To include your compound in the COVID-19 Resource Center, submit it here.

PKD: cease and de-cyst

Marketed treatments for polycystic kidney disease manage symptoms but do not slow disease progression. A research team led by Genzyme Corp. now has shown that blocking biosynthesis of the glycosphingolipid glucosylceramide could help treat the underlying causes of PKD.1 The findings could represent a new indication for Genzyme's eliglustat tartrate, a glucosylceramide synthase inhibitor that is in Phase III testing for Gaucher's disease.

The most common causes of PKD are mutations in polycystic kidney disease 1 (PKD1) or PKD2, both of which code for proteins that are expressed in the cilia of renal epithelial cells. Although different PKD mutations can produce a variety of symptoms, all forms of the disease are characterized by the development of cysts in the kidneys that compromise the organ's

Read the full 1233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers